Skip to main
AEMD
AEMD logo

Aethlon Medical (AEMD) Stock Forecast & Price Target

Aethlon Medical (AEMD) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Aethlon Medical Inc. has received constructive feedback from clinical sites aimed at enhancing patient enrollment and reducing screening failures, potentially leading to quicker data collection and more timely top-line readouts from ongoing studies. The Hemopurifier demonstrates promising capabilities in improving outcomes not only in oncology and infectious diseases but also in organ transplantation, highlighting the device's versatile applications and addressing significant unmet medical needs. With $4.8 million in cash and recent cost-cutting measures, Aethlon is well-positioned to sustain its operations into the second half of 2025, which may further support shareholder confidence amid advancements in their clinical programs.

Bears say

Aethlon Medical Inc is facing significant financial challenges, as evidenced by its reported net loss of $1.8 million in F3Q25, reflecting ongoing operational deficits. The company is exposed to numerous risks, including the potential failure of clinical trials and an untested commercialization strategy, which could hinder its ability to bring the Hemopurifier to market effectively. Additionally, the possible expiration or invalidation of intellectual property rights and difficulties in securing further funding in adverse market conditions contribute to a concerning outlook for the company’s financial stability.

Aethlon Medical (AEMD) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aethlon Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aethlon Medical (AEMD) Forecast

Analysts have given Aethlon Medical (AEMD) a Buy based on their latest research and market trends.

According to 2 analysts, Aethlon Medical (AEMD) has a Buy consensus rating as of Sep 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aethlon Medical (AEMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.